Public Profile

Laboratoire français du Fractionnement et des Biotechnologies

Laboratoire français du Fractionnement et des Biotechnologies (LFB) is a leading biopharmaceutical company headquartered in France, with significant operations across Europe and North America. Founded in 1994, LFB has established itself as a key player in the biopharmaceutical industry, specialising in the development and production of innovative therapies derived from human plasma. LFB's core offerings include a range of plasma-derived medicinal products, particularly in the fields of immunology, haematology, and critical care. What sets LFB apart is its commitment to high-quality standards and advanced biotechnological processes, ensuring the safety and efficacy of its products. With a strong market position, LFB has achieved notable milestones, including the expansion of its product portfolio and global reach, solidifying its reputation as a trusted provider in the biopharmaceutical sector.

DitchCarbon Score

How does Laboratoire français du Fractionnement et des Biotechnologies's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

26

Industry Average

Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

24

Industry Benchmark

Laboratoire français du Fractionnement et des Biotechnologies's score of 26 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.

66%

Let us know if this data was useful to you

Laboratoire français du Fractionnement et des Biotechnologies's reported carbon emissions

Laboratoire français du Fractionnement et des Biotechnologies currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In terms of climate commitments, there are no documented reduction targets or initiatives outlined in the available information. This absence of data suggests that the organisation may still be in the early stages of developing a comprehensive climate strategy or may not have publicly committed to specific emissions reduction goals at this time. As the industry increasingly prioritises sustainability, it will be essential for Labouratoire français du Fractionnement et des Biotechnologies to establish clear climate commitments and reduction targets to align with global efforts in combating climate change.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Laboratoire français du Fractionnement et des Biotechnologies's primary industry is Real estate services (70), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Laboratoire français du Fractionnement et des Biotechnologies is in FR, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Laboratoire français du Fractionnement et des Biotechnologies is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Genentech

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Joint Stock Company Pharmstandard

RU
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Novo Nordisk A Slash S

DK
Pharmaceutical Preparation Manufacturing
Updated about 1 hour ago

KMD

DK
Computer and related services (72)
Updated 3 days ago

Itron

US
Research and development services (73)
Updated 3 days ago

Harmonic Drive Systems

JP
Computer and related services (72)
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers